Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (NIVORAD)

Next Previous
X
Search
Trial Profile

A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (NIVORAD)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NIVORAD
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 11 Jul 2019 Status changed from recruiting to discontinued.
    • 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, two out of 20 sites are open for enrollment as of Feb 2017
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top